Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
3.030
+0.220 (7.83%)
May 27, 2025, 3:26 PM - Market open
Solid Biosciences Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Solid Biosciences stock ranges from a low of $10 to a high of $20. The average analyst price target of $14.9 forecasts a 391.75% increase in the stock price over the next year.
Price Target: $14.90 (+391.75%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Solid Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Buy | 8 | 8 | 8 | 8 | 8 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $16 | Buy | Initiates | $16 | +428.05% | May 22, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $16 → $15 | Strong Buy | Maintains | $16 → $15 | +395.05% | May 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +461.06% | May 16, 2025 |
| Wedbush | Wedbush | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +461.06% | May 16, 2025 |
| Barclays | Barclays | Buy Maintains $15 → $10 | Buy | Maintains | $15 → $10 | +230.03% | May 16, 2025 |
Financial Forecast
Revenue This Year
255.00K
Revenue Next Year
n/a
from 255.00K
EPS This Year
-2.23
from -3.06
EPS Next Year
-2.34
from -2.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2M | n/a | 134.4M | ||
| Avg | 255,000 | n/a | 29.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.68 | -1.46 | -1.56 | ||
| Avg | -2.23 | -2.34 | -2.42 | ||
| Low | -2.98 | -4.51 | -4.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.